96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05407766 (ClinicalTrials.gov) | August 2022 | 9/5/2022 | Mesenchymal Stem Cells (MSCs) for Perianal Fistula | A Phase I Safety Study of Allogeneic Bone Marrow Derived MSCs for Refractory Perianal Fistulizing Crohn's Disease | Rectal Fistula | Biological: OSSM-001;Other: Placebo | Ossium Health, Inc. | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 1 | NULL |
| 2 | NCT05578508 (ClinicalTrials.gov) | April 2022 | 1/11/2019 | Stem Cells for the Treatment of Pouchitis | A Phase I Study of Bone Marrow Derived Mesenchymal Stem Cells (MSCs) for the Treatment of Medically Refractory Pouchitis | Pouchitis;Crohn's Disease;Ulcerative Colitis Chronic;Inflammatory Bowel Diseases;Pouch, Ileal | Drug: Mesenchymal Stem Cells (MSCs) | The Cleveland Clinic | Case Western Reserve University | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 1 | United States |
| 3 | NCT05075811 (ClinicalTrials.gov) | February 1, 2022 | 28/9/2021 | Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease | A Phase IB/IIA Study of Ossium Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch | Pouch, Ileal;Fistula | Drug: Ossium vBM-MSC;Other: Placebo | Amy Lightner | Ossium Health, Inc. | Recruiting | 18 Years | 75 Years | All | 20 | Phase 1/Phase 2 | United States |
| 4 | NCT05039411 (ClinicalTrials.gov) | January 1, 2022 | 1/9/2021 | Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease | A Phase I Study of the Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for Perianal Fistulas in Patients With Crohn's Disease | Perianal Fistula Due to Crohn's Disease;Fistula in Ano | Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs) | CryoCord Sdn Bhd | University of Malaya | Not yet recruiting | 18 Years | N/A | All | 7 | Phase 1 | Malaysia |
| 5 | NCT04073472 (ClinicalTrials.gov) | June 1, 2021 | 23/8/2019 | Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's | A Phase I Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Ileal Anal Anastomosis and Ileal Pouch Fistulas in the Setting of Crohn's Disease of the Pouch | Crohn's Disease;Fistula;Anal Fistula;Pouch, Ileal;Pouches, Ileoanal | Drug: mesenchymal stem cells (MSCs) | The Cleveland Clinic | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 1 | United States |
| 6 | NCT03449069 (ClinicalTrials.gov) | July 23, 2018 | 22/2/2018 | Pediatric MSC-AFP Sub-study for Crohn's Fistula | A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study | Fistula in Ano;Crohn Disease | Drug: MSC-AFP | Mayo Clinic | NULL | Recruiting | 12 Years | 17 Years | All | 5 | Phase 1 | United States |
| 7 | NCT03901235 (ClinicalTrials.gov) | January 15, 2018 | 4/3/2019 | MSC Intratissular Injection in Crohn Disease Patients | Treatment of Refractory Crohn's Disease Lesions by Local Injection of Mesenchymal Stem Cells | Efficacy and Safety | Biological: Mesenchymal Stromal Cells | University of Liege | Centre Hospitalier Universitaire de Liege | Recruiting | 18 Years | N/A | All | 60 | Phase 1/Phase 2 | Belgium |
| 8 | NCT03220243 (ClinicalTrials.gov) | October 19, 2017 | 14/7/2017 | Stem Cell Coated Fistula Plug in Patients With Crohn's RVF | A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Rectovaginal Fistulizing Crohn's Disease | Fistula Vagina;Crohn Disease | Drug: MSC-AFP | Mayo Clinic | NULL | Completed | 18 Years | 65 Years | Female | 5 | Phase 1 | United States |
| 9 | NCT03014219 (ClinicalTrials.gov) | July 2017 | 4/1/2017 | Phase 1 Crohn's Pediatric Sub-study of MSC AFP | A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study | Perianal Fistula | Drug: Only 1 arm: treatment with MSC-AFP | William A. Faubion, M.D. | NULL | Withdrawn | 12 Years | 17 Years | All | 0 | Phase 1 | United States |
| 10 | NCT03056664 (ClinicalTrials.gov) | January 2017 | 24/8/2015 | The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease | The Safety and Efficiacy of Local MSC Injection in the Treatment of Fistulas in Patients With Perianal Crohn's Disease | Crohn's Disease;Fistula | Procedure: Routine drainage surgery;Biological: MSC injection 01;Biological: MSC injection 02;Other: placebo | Sixth Affiliated Hospital, Sun Yat-sen University | NULL | Not yet recruiting | 18 Years | 65 Years | All | 3 | Phase 2/Phase 3 | NULL |
| 11 | NCT02532738 (ClinicalTrials.gov) | January 2016 | 23/8/2015 | The Efficiency of MSC in Refractory Crohn's Disease | A Stage II Clinical Trial Comparing the Efficiacy of Routine Treatment Combined With or Without MSC Therapy in Refractory Crohn's Disease | Crohn's Disease | Drug: Routine Treatment of CD;Biological: MSC treatment 01;Biological: MSC treatment 02;Other: NS | Sixth Affiliated Hospital, Sun Yat-sen University | Third Affiliated Hospital, Sun Yat-Sen University;Nanfang Hospital of Southern Medical University | Not yet recruiting | 18 Years | 65 Years | Both | 3 | Phase 2/Phase 3 | NULL |
| 12 | NCT01915927 (ClinicalTrials.gov) | July 2013 | 31/7/2013 | Stem Cell Fistula Plug in Perianal Crohn's Disease | A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease. | Perianal Crohn's Disease | Drug: MSC-AFP | William A. Faubion, M.D. | NULL | Completed | 18 Years | 65 Years | All | 20 | Phase 1 | United States |
| 13 | NCT01540292 (ClinicalTrials.gov) | February 1, 2013 | 22/2/2012 | Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders | Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders | Crohn's Disease | Biological: Mesenchymal Stem Cells (MSC) | University of Liege | NULL | Terminated | 18 Years | 75 Years | All | 13 | Phase 1/Phase 2 | Belgium |
| 14 | NCT01659762 (ClinicalTrials.gov) | July 2012 | 6/8/2012 | A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease. | A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stromal (MSC) Cells in Adults With Moderate to Severe Crohn's Disease. | Crohn's Disease | Biological: autologous mesenchymal stromal cell | Emory University | Atlanta Clinical and Translational Science Institute;Atlanta Clinical and Translational Science Institute | Completed | 18 Years | 65 Years | Both | 16 | Phase 1 | United States |
| 15 | NCT02445547 (ClinicalTrials.gov) | June 2012 | 13/5/2015 | Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease | Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial | Crohn Disease | Other: UC-MSCs by peripheral intravenous infusion;Drug: received hormone maintenance therapy | Fuzhou General Hospital | Shaanxi Provincial People's Hospital | Completed | 18 Years | 70 Years | All | 82 | Phase 1/Phase 2 | China |
| 16 | EUCTR2011-005966-39-BE (EUCTR) | 08/03/2012 | 12/12/2011 | Therapeutic effect of mesenchymal cells in patients suffering from a disease characterized by a severe inflammation and/or in whom the immune system attacks their own tissues. | Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders. | Crohn's disease MedDRA version: 14.0;Level: LLT;Classification code 10011402;Term: Crohn's disease (colon);System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.0;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders;System Organ Class: 10021428 - Immune system disorders MedDRA version: 14.0;Level: PT;Classification code 10064147;Term: Gastrointestinal inflammation;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: mesenchymal stem cells Product Code: MSC | CHU-ULg | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Belgium | |||
| 17 | EUCTR2009-015680-14-NL (EUCTR) | 18/05/2010 | 27/07/2010 | Allogeneic Bone Marrow Derived Mesenchymal Stem Cellsfor the Treatment of Fistulas in Patients withRefractory Perianal Crohn’s Disease - allo bmMSCs CD fistula | Allogeneic Bone Marrow Derived Mesenchymal Stem Cellsfor the Treatment of Fistulas in Patients withRefractory Perianal Crohn’s Disease - allo bmMSCs CD fistula | single or multiple draining perianal fistulas as a result of Crohn's Disease MedDRA version: 12.1;Level: LLT;Classification code 10011401;Term: Crohn's disease | Product Name: Bone Marrow Derived Mesenchymal Stem cells (MSCs) Product Code: NA | Leiden University Medical Center | NULL | Not Recruiting | Female: yes Male: yes | Netherlands | ||||
| 18 | NCT01090817 (ClinicalTrials.gov) | January 2010 | 22/3/2010 | An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease | A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's Disease | Crohn Disease | Drug: Mesenchymal stromal cells (MSC) for infusion | R.P.Herrmann | The Queen Elizabeth Hospital;Concord Hospital;Sir Charles Gairdner Hospital;The Alfred | Completed | 18 Years | 55 Years | Both | 21 | Phase 2 | Australia |